8-K: Avenue Therapeutics Sets 2025 Annual Meeting Date
Annual Meeting Announcement
Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its annual meeting of stockholders and established deadlines for shareholder proposals and director nominations.
Summary
- Avenue Therapeutics, Inc. has scheduled its 2025 annual meeting of stockholders for December 30, 2025.
- The specific time and location of the Annual Meeting will be detailed in the definitive proxy statement on Schedule 14A, which will be filed with the SEC.
- Shareholders wishing to submit proposals for inclusion in the proxy statement under Rule 14a-8 must ensure their proposals are received by the company no later than November 28, 2025.
- Shareholders intending to submit proposals or nominate directors outside of Rule 14a-8 must also provide notice to the company by the close of business on November 28, 2025.
- To comply with universal proxy rules, stockholders soliciting proxies for director nominees other than the company's must notify the Corporate Secretary by November 28, 2025.
- All proposals and notices must be in writing and sent to the Corporate Secretary at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154, adhering to Exchange Act rules and company Bylaws.
Sentiment
Score: 5
Explanation: The filing is purely administrative, announcing the annual meeting date and related deadlines. It contains no financial or operational news that would typically influence sentiment.
Future Outlook
The company will file its definitive proxy statement on Schedule 14A for the Annual Meeting, which will include the time and location of the meeting.
Industry Context
This is a routine administrative announcement common for publicly traded companies, fulfilling regulatory requirements to inform shareholders about the upcoming annual meeting and associated deadlines for corporate governance matters.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Procedural Announcement | Announcement of the 2025 Annual Meeting of Stockholders and the deadlines for shareholder proposals and director nominations, in accordance with the company's Second Amended and Restated Bylaws and Exchange Act rules, including universal proxy rules. | 2025-11-14 | Ensures compliance with corporate governance requirements and provides shareholders with necessary information and deadlines for participation in the annual meeting process. |
Stakeholder Impact
- Shareholders: Provided with the date of the annual meeting and deadlines to submit proposals or nominate directors, enabling their participation in corporate governance.
Next Steps
- Filing of the definitive proxy statement on Schedule 14A with the SEC, which will specify the time and location of the Annual Meeting.
- Shareholders to submit proposals or director nominations by November 28, 2025, if applicable.
Key Dates
| Date | Description |
|---|---|
| 2025-11-14 | Date of earliest event reported (public announcement of Annual Meeting date) |
| 2025-11-18 | Date of signing of the 8-K report |
| 2025-11-28 | Deadline for shareholder proposals for inclusion in proxy statement (Rule 14a-8) |
| 2025-11-28 | Deadline for shareholder proposals or director nominations outside Rule 14a-8 |
| 2025-11-28 | Deadline for notice from stockholders soliciting proxies for director nominees (universal proxy rules) |
| 2025-12-30 | Date of the 2025 Annual Meeting of Stockholders |
Keywords
Avenue Therapeutics, ATXI, Annual Meeting, Shareholder Proposals, Director Nominations, Corporate Governance, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.